Supplementary Figures 1-7, Tables 1-4 from Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

PDF file - 507K, Supplemental Table 1A: PCR and Sanger Sequencing Primers Supplemental Table 1B: PCR and Sequenom Genotyping Primers Supplemental Figure 1. Kaplan-Meier estimates of disease free survival for BCIRG 006 study, entire population, third planned analysis. (N=3222) Supplemental Table 2. Patient Characteristics: Genotyped vs. Non-genotyped Supplemental Figure 2. Kaplan-Meier estimates of disease free survival in subset of patients enrolled in BCIRG006 (third planned analysis) who were genotyped for this study (N=1,286) Supplemental Figure 3. Kaplan-Meier estimates of disease free survival in subset of patients enrolled in BCIRG006 (third planned analysis) who were genotyped for this study with stratification for major prognostic factors Supplemental Table 3. Patients Characteristics by Genotype (Advanced Disease Cohort) Supplemental Table 4. Genotype and Allele Frequencies of the FCGR2A and FCGR3A Polymorphisms Supplemental Figure 4. Kaplan-Meier estimates of disease free survival in trastuzumab treated patients within the adjuvant cohort according to FcGammaR polymorphisms, broken down by treatment arm Supplemental Figure 5. Kaplan-Meier estimates of disease free survival in patients treated with chemotherapy alone (no trastuzumab) in the adjuvant cohort according to FcGammaR polymorphisms, broken down by treatment arm. Supplemental Figure 6. Kaplan-Meier estimates of overall survival (OS) in trastuzumab treated patients within the adjuvant cohort according to FcGammaR polymorphisms. Supplemental Figure 7. Kaplan-Meier estimates of progression free survival (PFS) in trastuzumab treated patients within the advanced disease cohort according to FcGammaR polymorphisms.